A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

This study is investigating the effects of a new hormone treatment for breast cancer called Irosustat. Seventy percent of breast cancers in post-menopausal wome rely on oestrogen to grow therefore are likely to respond to hormone therapy. Irosustat blocks a different pathway of steroid synthesis to Aromatase, reducing in this way oestrogen levels in the body. As less oestrogen reaches the breast cancer, it grows more slowly or stops growing altogether.

IPET will recruit postmenopausal women with early, hormone sensitive, treatment naive breast cancer will receive 40mg of Irosustat once daily for 2 weeks. The effects of Irosustat on breast cancer will be evaluated by PET scans (Positron Emission Tomography) using a radioactive substance called FLT as a tracer. The scans will be performed in a PET-CT scanner which combines a PET scan and a CT scan (Computer Tomography) into one scan. This type of scan can show how body tissues are working, as well as what they look like. FLT-PET scans will be performed before and following treatment with Irosustat. As cancer cells grow faster than the normal cells around them, they will take up more of the radioactive substance, and so stand out clearly on the scan. If Irosustat is slowing down the cancer growth, the cancer will take up less of the tracer.

Blood samples will be taken at regular intervals to assess what the new drug does to the body and the safety and tolerability of Irosustat will be assessed. The study incorporates translation aspects/endpoints which are based on the collection of tumour biopsies before and after treatment with Irosustat although the later biopsy is not mandatory.

Objectives

Primary:

To assess changes in \[18F\] fluorothymidine (FLT) uptake using Positron Emission Tomography (PET) following 2 weeks of Irosustat treatment in patients with early, treatment naïve, oestrogen receptor positive (ER +ve) breast cancer

Secondary:

To assess the:

1. Pharmacodynamic profile of Irosustat
2. Safety and tolerability of Irosustat

Study Population: Postmenopausal women with early, treatment naïve, ER +ve breast cancer

Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent to participate in the trial
2. 18 years of age or older
3. Histologically confirmed ER +ve breast cancer (Allred ≥ 3)
4. Any HER2 status
5. Tumour measuring ≥ 15mm in longest diameter on ultrasound (US) examination
6. Postmenopausal women as defined by any one of the following criteria:

   * Amenorrhoea \> 12 months at the time of diagnosis and an intact uterus OR,
   * prior bilateral oophorectomy OR,
   * FSH levels within the postmenopausal range (as per local practice) in women aged \< 55years who have undergone hysterectomy OR,
   * FSH levels within the postmenopausal range (as per local practice) in women aged \< 55 years who have been on Hormone Replacement Therapy (HRT) within the last 12 months and are therefore not amenorrhoeic
7. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
8. Adequate bone marrow function defined by Hb ≥ 10 g/dl, WBC ≥ 3.0 x109, PLT ≥ 100 x109/L. Adequate renal function defined by a serum creatinine ≤ 1.5 x ULN. Adequate liver function defined by total bilirubin ≤ 1.5 ULN (patients with Gilbert's syndrome exempted), either ALT or AST ≤ 1.5 ULN and ALP ≤ 1.5 ULN

Exclusion Criteria:

1. Locally advanced/inoperable breast cancer
2. Clinical evidence of metastatic disease
3. Diffuse or inflammatory tumours
4. Any history of invasive malignancy within 5 years of starting study treatment (other than adequately treated basal cell carcinoma or squamous cell carcinoma of the skin and cervical carcinoma in situ)
5. Evidence of bleeding diathesis and PTT and PT ≤ 1.5 x upper limit of normal
6. Concomitant use (defined as use within 4 weeks prior to entry) of HRT or any other oestrogen-containing medication or supplement (including vaginal oestrogens and phytoestrogens)
7. Previous use of oestrogen implants at ANY time.
8. Concomitant use of:

   * Rifampicin and other CYP2C and 3A inducers such as rifabutin, rifapentine, carbamazepine, phenobarbital, phenytoin and St. John's Wort
   * Systemic carbonic anhydrase inhibitors
9. Any of the following cardiac criteria:

   * Mean resting corrected QT interval (QTcf) \> 450 ms obtained from 3 electrocardiograms (ECGs)
   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block
   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
10. Uncontrolled abnormalities of serum potassium, sodium, calcium or magnesium levels
11. Evidence of uncontrolled active infection
12. Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial
13. Subjects unable to lie flat or fit into the scanner
14. Patients on occupational monitoring for radiation exposure